Search Browse Earnings

Inozyme Pharma, Inc. — SlamSEC

Inozyme Pharma, Inc.

Pharmaceutical Preparations·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$74.8M

FY 2024

Net Income

-$71.2M

FY 2024

EPS (Diluted)

-$1.37

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$34.6M

FY 2024

Total Debt

$59.3M

FY 2024

Net Debt

$24.7M

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.3x

FY 2024

EV / EBITDA

—

Employees

—